Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, reported positive data for the ALN-RSV01 Phase II experimental infection study, now called "GEMINI." The GEMINI study was designed to evaluate the safety and anti-viral activity of ALN-RSV01, an RNAi therapeutic for the treatment of RSV infection. Top-line results show that ALN-RSV01 was safe and well tolerated and demonstrated statistically significant anti-viral activity.
(more...)